Antisense therapy: potential tool to reduce activity in MS via protein expression inhibition

Neurology. 2014 Nov 11;83(20):1776-7. doi: 10.1212/WNL.0000000000000927. Epub 2014 Sep 19.

Authors

Robert T Naismith¹, Anne H Cross²

Affiliations

¹ From the Department of Neurology (R.T.N., A.H.C.) and Hope Center for Neurological Disorders (A.H.C.), Washington University School of Medicine, St. Louis, MO.
² From the Department of Neurology (R.T.N., A.H.C.) and Hope Center for Neurological Disorders (A.H.C.), Washington University School of Medicine, St. Louis, MO. crossa@neuro.wustl.edu.

PMID: 25239837
DOI: 10.1212/WNL.0000000000000927

No abstract available

Publication types

Editorial
Comment

MeSH terms

Female
Humans
Integrin alpha4 / chemistry*
Integrin alpha4 / genetics*
Male
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Oligodeoxyribonucleotides, Antisense / therapeutic use*

Substances

Oligodeoxyribonucleotides, Antisense
Integrin alpha4